Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PURR-11
- Development stage
- Preclinical
- Lead developer
- The Cat Health Company
- Modality
- Small Molecules
01
Overview
PURR-11 is a pipeline drug candidate being developed by **The Cat Health Company** (also known as The Cat Co), a biotechnology firm dedicated to extending the healthy lifespan of domestic cats. As part of the company's "PURR" series of longevity therapeutics, PURR-11 is intended to address common age-related pathologies in senior felines, specifically **sarcopenia** (muscle wasting), **chronic kidney disease (CKD)**, and **neurodegeneration**. The development of PURR-11 reflects the company's broader strategy of identifying and developing medicines that target the fundamental biological drivers of aging to improve health outcomes and extend the healthspan of the aging cat population.
Beyond the preview
Go deeper on PURR-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PURR-11.